The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ROIV | +53.11% | N/A | N/A | +72% |
| S&P | +14.5% | +93.32% | +14.09% | +81% |
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.
Investors were in a forgiving mood after Monday's dispiriting earnings release.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.17M | -96.1% |
| Gross Profit | $0.92M | -98.1% |
| Gross Margin | 42.30% | -45.9% |
| Market Cap | $7.66B | -1.9% |
| Market Cap / Employee | $10.22M | 0.0% |
| Employees | 750 | -17.4% |
| Net Income | -$273.91M | -576.4% |
| EBITDA | -$283.82M | -25.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.24B | -78.2% |
| Accounts Receivable | $0.68M | -98.3% |
| Inventory | 0 | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $90.29M | -74.7% |
| Short Term Debt | $9.40M | -56.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.44% | -123.2% |
| Return On Invested Capital | -14.40% | 3.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$208.42M | -7.5% |
| Operating Free Cash Flow | -$204.38M | -6.0% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 2.16 | 2.08 | 1.90 | 2.04 | - |
| Price to Book | 1.64 | 1.68 | 1.40 | 1.67 | 17.12% |
| Price to Sales | 67.53 | 87.64 | 93.66 | 330.00 | 532.30% |
| Price to Tangible Book Value | 1.64 | 1.68 | 1.40 | 1.67 | 14.41% |
| Enterprise Value to EBITDA | -10.44 | -14.12 | -10.04 | -13.15 | -13.16% |
| Return on Equity | 159.1% | -7.1% | -8.6% | -15.8% | -110.61% |
| Total Debt | $52.71M | $100.31M | $100.17M | $99.69M | -73.70% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
